Market closed

Agios/$AGIO

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Agios

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Ticker

$AGIO
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Cambridge, United States

Employees

385
Website
www.agios.com

Agios Metrics

BasicAdvanced
$2B
2.91
$11.80
0.75
-

$2B

0.75

$59.29

$20.96

1.1M

8.993

8.438

2.737

3.74

-18.17%

53.65%

2.907

58.97

1.2

1.2

-5.872

36.79%

-397.66%

-22.09%

What the Analysts think about Agios

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Agios stock.

Agios Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Agios Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Agios News

AllArticlesVideos
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

GlobeNewsWire·2 weeks ago
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease

European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease

GlobeNewsWire·4 weeks ago
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AGIO

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Agios stock?

Agios (AGIO) has a market cap of $2B as of January 15, 2025.

What is the P/E ratio for Agios stock?

The price to earnings (P/E) ratio for Agios (AGIO) stock is 2.91 as of January 15, 2025.

Does Agios stock pay dividends?

No, Agios (AGIO) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Agios dividend payment date?

Agios (AGIO) stock does not pay dividends to its shareholders.

What is the beta indicator for Agios?

Agios (AGIO) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.